$NBIX
NEUROCRINE BIOSCIENCES INC

2017 Q1 Form 10-Q Financial Statement

#000119312517164338 Filed on May 09, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q4 2016 Q1
Revenue $0.00 $0.00 $15.00M
YoY Change -100.0% -24.12%
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $28.05M $23.70M $12.00M
YoY Change 133.75% 166.29% 118.18%
% of Gross Profit
Research & Development $51.88M $22.60M $23.90M
YoY Change 117.05% 3.67% 44.21%
% of Gross Profit
Depreciation & Amortization $500.0K $500.0K $300.0K
YoY Change 66.67% 66.67% 50.0%
% of Gross Profit
Operating Expenses $79.93M $46.25M $35.86M
YoY Change 122.92% 50.42% 62.57%
Operating Profit -$79.93M -$20.86M
YoY Change 283.24% 811.58%
Interest Expense $0.00 $700.0K $700.0K
YoY Change -100.0% 16.67% 133.33%
% of Operating Profit
Other Income/Expense, Net $1.606M $900.0K $1.593M
YoY Change 0.82% 12.5% 45.35%
Pretax Income -$78.30M -$44.70M -$19.30M
YoY Change 305.7% 52.56% 1508.33%
Income Tax
% Of Pretax Income
Net Earnings -$78.33M -$44.66M -$19.26M
YoY Change 306.59% 52.34% 1516.11%
Net Earnings / Revenue -128.43%
Basic Earnings Per Share -$0.90
Diluted Earnings Per Share -$0.90 -$514.4K -$223.1K
COMMON SHARES
Basic Shares Outstanding 87.28M 86.87M shares 86.45M shares
Diluted Shares Outstanding 87.28M

Balance Sheet

Concept 2017 Q1 2016 Q4 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $235.6M $307.4M $381.5M
YoY Change -38.24% -18.93% 3.11%
Cash & Equivalents $64.09M $83.27M $115.3M
Short-Term Investments $171.5M $224.1M $266.2M
Other Short-Term Assets $3.871M $3.092M $4.377M
YoY Change -11.56% -36.68% -10.96%
Inventory $0.00
Prepaid Expenses
Receivables $0.00 $15.10M
Other Receivables $0.00
Total Short-Term Assets $239.5M $310.4M $401.0M
YoY Change -40.28% -19.17% -0.98%
LONG-TERM ASSETS
Property, Plant & Equipment $7.144M $6.271M $3.897M
YoY Change 83.32% 82.72% 53.24%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $37.70M $43.50M $49.50M
YoY Change -23.84% -47.27% -57.14%
Other Assets $5.100M $4.900M $5.000M
YoY Change 2.0% 2.08% 4.17%
Total Long-Term Assets $49.91M $54.64M $58.35M
YoY Change -14.46% -39.76% -52.5%
TOTAL ASSETS
Total Short-Term Assets $239.5M $310.4M $401.0M
Total Long-Term Assets $49.91M $54.64M $58.35M
Total Assets $289.4M $365.1M $459.3M
YoY Change -37.0% -23.1% -12.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $852.0K $5.085M $2.122M
YoY Change -59.85% 98.56% 67.09%
Accrued Expenses $18.40M $21.10M $17.13M
YoY Change 7.46% 10.84% 72.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $23.56M $30.41M $23.28M
YoY Change 1.23% 18.27% 53.26%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $113.0K $113.0K $221.0K
YoY Change -48.87% -48.87% -15.0%
Total Long-Term Liabilities $113.0K $113.0K $221.0K
YoY Change -48.87% -48.87% -15.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $23.56M $30.41M $23.28M
Total Long-Term Liabilities $113.0K $113.0K $221.0K
Total Liabilities $42.22M $50.21M $46.37M
YoY Change -8.95% -0.24% 7.72%
SHAREHOLDERS EQUITY
Retained Earnings -$1.135B -$1.056B -$934.5M
YoY Change 21.42% 15.42% 12.93%
Common Stock $1.382B $1.372B $1.348B
YoY Change 2.55% 2.3% 1585364.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $247.1M $314.9M $413.0M
YoY Change
Total Liabilities & Shareholders Equity $289.4M $365.1M $459.3M
YoY Change -37.0% -23.1% -12.97%

Cashflow Statement

Concept 2017 Q1 2016 Q4 2016 Q1
OPERATING ACTIVITIES
Net Income -$78.33M -$44.66M -$19.26M
YoY Change 306.59% 52.34% 1516.11%
Depreciation, Depletion And Amortization $500.0K $500.0K $300.0K
YoY Change 66.67% 66.67% 50.0%
Cash From Operating Activities -$77.40M -$31.60M -$29.20M
YoY Change 165.07% 107.89% 60.44%
INVESTING ACTIVITIES
Capital Expenditures $1.362M -$300.0K $741.0K
YoY Change 83.81% -62.5% 164.64%
Acquisitions
YoY Change
Other Investing Activities $58.00M $15.50M $71.00M
YoY Change -18.31% -32.31% -161.31%
Cash From Investing Activities $56.60M $15.20M $70.30M
YoY Change -19.49% -31.22% -160.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.531M $62.00K
YoY Change 2369.35% -99.98%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.500M 100.0K 100.0K
YoY Change 1400.0% -90.0% -99.96%
NET CHANGE
Cash From Operating Activities -77.40M -31.60M -29.20M
Cash From Investing Activities 56.60M 15.20M 70.30M
Cash From Financing Activities 1.500M 100.0K 100.0K
Net Change In Cash -19.30M -16.30M 41.20M
YoY Change -146.84% -306.33% -70.4%
FREE CASH FLOW
Cash From Operating Activities -$77.40M -$31.60M -$29.20M
Capital Expenditures $1.362M -$300.0K $741.0K
Free Cash Flow -$78.76M -$31.30M -$29.94M
YoY Change 163.06% 117.36% 62.02%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
88074963 shares
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
115301000
CY2016Q1 nbix Cease Use Liability
CeaseUseLiability
1043000
CY2017Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
220000000 shares
CY2017Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
87519910 shares
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
87519910 shares
CY2017Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1134650000
CY2017Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2017Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
113000
CY2017Q1 us-gaap Liabilities
Liabilities
42223000
CY2017Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
289364000
CY2017Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-235000
CY2017Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
852000
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
247141000
CY2017Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
10231000
CY2017Q1 us-gaap Common Stock Value
CommonStockValue
88000
CY2017Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1381938000
CY2017Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1305000
CY2017Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q1 us-gaap Sale Leaseback Transaction Deferred Gain Net
SaleLeasebackTransactionDeferredGainNet
10000000
CY2017Q1 us-gaap Liabilities Current
LiabilitiesCurrent
23563000
CY2017Q1 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
513000
CY2017Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18403000
CY2017Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
CY2017Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
244000
CY2017Q1 us-gaap Assets Current
AssetsCurrent
239451000
CY2017Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
187847000
CY2017Q1 us-gaap Other Assets Current
OtherAssetsCurrent
3871000
CY2017Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7144000
CY2017Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
5083000
CY2017Q1 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
171493000
CY2017Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
187847000
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64087000
CY2017Q1 us-gaap Investments
Investments
209200000
CY2017Q1 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
37686000
CY2017Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
244000
CY2017Q1 us-gaap Assets
Assets
289364000
CY2017Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
209179000
CY2017Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
0
CY2017Q1 nbix Number Of Renewal Options
NumberOfRenewalOptions
2 RenewalOptions
CY2017Q1 nbix Letters Of Credit Collateral
LettersOfCreditCollateral
4600000
CY2017Q1 nbix Deferred Gain On Sale Of Real Estate Noncurrent
DeferredGainOnSaleOfRealEstateNoncurrent
6467000
CY2017Q1 nbix Cease Use Liability Noncurrent
CeaseUseLiabilityNoncurrent
544000
CY2017Q1 nbix Cease Use Liability Current
CeaseUseLiabilityCurrent
243000
CY2017Q1 nbix Deferred Gain On Sale Of Real Estate Current
DeferredGainOnSaleOfRealEstateCurrent
3552000
CY2017Q1 nbix Cease Use Liability
CeaseUseLiability
787000
CY2008Q4 us-gaap Sale Leaseback Transaction Deferred Gain Net
SaleLeasebackTransactionDeferredGainNet
39100000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74195000
CY2015Q4 nbix Cease Use Liability
CeaseUseLiability
1983000
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
220000000 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
86883300 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
86883300 shares
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1056324000
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
113000
CY2016Q4 us-gaap Liabilities
Liabilities
50209000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
365086000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-318000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5085000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
314877000
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
10231000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
87000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1371432000
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1462000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
30414000
CY2016Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
470000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21097000
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
3000
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
324000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
310442000
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
241956000
CY2016Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3092000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6271000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4883000
CY2016Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
224083000
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
251100000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
83267000
CY2016Q4 us-gaap Investments
Investments
267600000
CY2016Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
43490000
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
321000
CY2016Q4 us-gaap Assets
Assets
365086000
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
267573000
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
9144000
CY2016Q4 nbix Deferred Gain On Sale Of Real Estate Noncurrent
DeferredGainOnSaleOfRealEstateNoncurrent
7372000
CY2016Q4 nbix Cease Use Liability Noncurrent
CeaseUseLiabilityNoncurrent
617000
CY2016Q4 nbix Cease Use Liability Current
CeaseUseLiabilityCurrent
236000
CY2016Q4 nbix Deferred Gain On Sale Of Real Estate Current
DeferredGainOnSaleOfRealEstateCurrent
3526000
CY2016Q4 nbix Cease Use Liability
CeaseUseLiability
853000
CY2007Q4 us-gaap Mortgage Loans On Real Estate Cost Of Mortgages Sold
MortgageLoansOnRealEstateCostOfMortgagesSold
47700000
CY2007Q4 us-gaap Sale Leaseback Transaction Net Proceeds Financing Activities
SaleLeasebackTransactionNetProceedsFinancingActivities
61000000
CY2007Q4 us-gaap Sale Leaseback Transaction Gross Proceeds Investing Activities
SaleLeasebackTransactionGrossProceedsInvestingActivities
109000000
CY2007Q4 nbix Number Of Buildings Leased
NumberOfBuildingsLeased
2 Building
CY2007Q4 nbix Sale Leaseback Transaction Lease Period
SaleLeasebackTransactionLeasePeriod
P12Y
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1400000 shares
CY2017Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2017Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017Q1 dei Document Type
DocumentType
10-Q
CY2017Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000914475
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-77357000
CY2017Q1 us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
300000 shares
CY2017Q1 dei Trading Symbol
TradingSymbol
NBIX
CY2017Q1 dei Amendment Flag
AmendmentFlag
false
CY2017Q1 us-gaap Property Management Fee Percent Fee
PropertyManagementFeePercentFee
0.035 pure
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
87283000 shares
CY2017Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017Q1 dei Document Period End Date
DocumentPeriodEndDate
2017-03-31
CY2017Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2017Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
300000 shares
CY2017Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> <i>Use of Estimates</i>. The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.</p> </div>
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.90
CY2017Q1 dei Entity Registrant Name
EntityRegistrantName
NEUROCRINE BIOSCIENCES INC
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1400000 shares
CY2017Q1 us-gaap Revenues
Revenues
0
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1362000
CY2017Q1 us-gaap Investment Income Net
InvestmentIncomeNet
727000
CY2017Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-269000
CY2017Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
83000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-79932000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-78326000
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-78243000
CY2017Q1 us-gaap Licenses Revenue
LicensesRevenue
0
CY2017Q1 us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
779000
CY2017Q1 us-gaap Sale Leaseback Transaction Current Period Gain Recognized
SaleLeasebackTransactionCurrentPeriodGainRecognized
900000
CY2017Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
57877000
CY2017Q1 us-gaap Operating Leases Rent Expense Sublease Rentals1
OperatingLeasesRentExpenseSubleaseRentals1
600000
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1606000
CY2017Q1 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
200000
CY2017Q1 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
879000
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9000000
CY2017Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-114000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
56646000
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1531000
CY2017Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
8976000
CY2017Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
489000
CY2017Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
116085000
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28050000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1531000
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
51882000
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-19180000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-6927000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
79932000
CY2017Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1500000
CY2017Q1 nbix Lease Extension Period
LeaseExtensionPeriod
P10Y
CY2017Q1 nbix Subleased Agreement Area
SubleasedAgreementArea
16000 sqft
CY2017Q1 nbix Lease Expiration Year
LeaseExpirationYear
2019
CY2017Q1 nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
879000
CY2017Q1 nbix Nonoperating Gain Loss On Disposition Of Assets
NonoperatingGainLossOnDispositionOfAssets
0
CY2017Q1 nbix Increase Decrease In Cease Use Expense
IncreaseDecreaseInCeaseUseExpense
0
CY2017Q1 nbix Increase Decrease In Cease Use Liability
IncreaseDecreaseInCeaseUseLiability
-66000
CY2017Q1 nbix Cease Use Liability Payment
CeaseUseLiabilityPayment
66000
CY2017Q1 nbix Change In Estimate On Cease Use Liability
ChangeInEstimateOnCeaseUseLiability
0
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
500000 shares
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-29211000
CY2016Q1 us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
300000 shares
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
86497000 shares
CY2016Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
26000.0 shares
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
700000 shares
CY2016Q1 us-gaap Revenues
Revenues
15000000
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
741000
CY2016Q1 us-gaap Investment Income Net
InvestmentIncomeNet
737000
CY2016Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1397000
CY2016Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
789000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-20857000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-19264000
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18475000
CY2016Q1 us-gaap Licenses Revenue
LicensesRevenue
15000000
CY2016Q1 us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
14577000
CY2016Q1 us-gaap Sale Leaseback Transaction Current Period Gain Recognized
SaleLeasebackTransactionCurrentPeriodGainRecognized
900000
CY2016Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
55561000
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1593000
CY2016Q1 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
200000
CY2016Q1 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
856000
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6900000
CY2016Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-64000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
70255000
CY2016Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
62000
CY2016Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
3000
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
6918000
CY2016Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
276000
CY2016Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
126754000
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11954000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
62000
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23903000
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
41106000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2347000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
35857000
CY2016Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
100000
CY2016Q1 nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
853000
CY2016Q1 nbix Nonoperating Gain Loss On Disposition Of Assets
NonoperatingGainLossOnDispositionOfAssets
3000
CY2016Q1 nbix Increase Decrease In Cease Use Expense
IncreaseDecreaseInCeaseUseExpense
-584000
CY2016Q1 nbix Increase Decrease In Cease Use Liability
IncreaseDecreaseInCeaseUseLiability
-110000
CY2016Q1 nbix Cease Use Liability Payment
CeaseUseLiabilityPayment
110000
CY2016Q1 nbix Change In Estimate On Cease Use Liability
ChangeInEstimateOnCeaseUseLiability
-830000

Files In Submission

Name View Source Status
0001193125-17-164338-index-headers.html Edgar Link pending
0001193125-17-164338-index.html Edgar Link pending
0001193125-17-164338.txt Edgar Link pending
0001193125-17-164338-xbrl.zip Edgar Link pending
d345381d10q.htm Edgar Link pending
d345381dex311.htm Edgar Link pending
d345381dex312.htm Edgar Link pending
d345381dex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
nbix-20170331.xml Edgar Link completed
nbix-20170331.xsd Edgar Link pending
nbix-20170331_cal.xml Edgar Link unprocessable
nbix-20170331_def.xml Edgar Link unprocessable
nbix-20170331_lab.xml Edgar Link unprocessable
nbix-20170331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending